Verition Fund Management LLC Purchases 2,287 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Verition Fund Management LLC increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 193.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,470 shares of the medical research company's stock after purchasing an additional 2,287 shares during the period. Verition Fund Management LLC's holdings in Bio-Rad Laboratories were worth $1,161,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. PEAK6 Investments LLC bought a new position in shares of Bio-Rad Laboratories during the 3rd quarter worth approximately $956,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Bio-Rad Laboratories by 1.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company's stock valued at $147,583,000 after buying an additional 4,260 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Bio-Rad Laboratories by 8.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,332 shares of the medical research company's stock worth $2,119,000 after buying an additional 511 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of Bio-Rad Laboratories by 82.6% in the 3rd quarter. MetLife Investment Management LLC now owns 9,900 shares of the medical research company's stock valued at $3,312,000 after acquiring an additional 4,478 shares in the last quarter. Finally, Glenmede Trust Co. NA acquired a new position in shares of Bio-Rad Laboratories during the 3rd quarter worth approximately $351,000. Institutional investors own 65.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BIO. Citigroup upped their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target on the stock. Royal Bank of Canada lifted their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Stock Performance

Shares of BIO traded up $3.14 during midday trading on Friday, reaching $325.50. 151,252 shares of the stock were exchanged, compared to its average volume of 184,972. The stock's 50 day simple moving average is $341.22 and its 200 day simple moving average is $319.21. The company has a market cap of $9.11 billion, a P/E ratio of -11.91 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million during the quarter, compared to analysts' expectations of $628.18 million. During the same quarter in the previous year, the company earned $2.33 EPS. The business's revenue was up 2.8% on a year-over-year basis. On average, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.